67. Polycystic kidney disease Clinical trials / Disease details

Clinical trials : 216 / Drugs : 219 - (DrugBank : 50) / Drug target genes : 39 - Drug target pathways : 151

12 trials found

diseases per page:

Showing 1 to 10 of 12 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02055079 (ClinicalTrials.gov)	April 2014	31/1/2014	Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease	Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease - The Vienna RAP Study	Polycystic Kidney, Type 1 Autosomal Dominant Disease;Polycystic Kidney, Type 2 Autosomal Dominant Di ...	Drug: Sirolimus;Drug: Placebo	Medical University of Vienna	NULL	Unknown status	18 Years	N/A	All	68	Phase 3	Austria
2	EUCTR2012-000550-60-AT (EUCTR)	17/01/2014	27/11/2013	Pulsed oral sirolimus in autosomal dominant polycystic kidney disease	Pulsed oral sirolimus in autosomal dominant polycystic kidney disease - The Vienna RAP Study	Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by the deve ...	Trade Name: Rapamune 1mg tablets Product Name: Rapamune 1mg tablets INN or Proposed INN: SIROLIMUS	Medizinische Universität Wien, Klinische Abteilung für Nephrologie und Dialyse, Universitätsklinik f ...	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	68	Phase 3	Austria
3	NCT01680250 (ClinicalTrials.gov)	September 2011	30/8/2012	Sirolimus for Massive Polycystic Liver	An Open-label, Prospective Clinical Trial to Evaluate the Effectiveness and Safety of Sirolimusto Re ...	Polycystic Kidney Diseases	Drug: Sirolimus	Seoul National University Hospital	Wyeth is now a wholly owned subsidiary of Pfizer	Recruiting	18 Years	65 Years	Both	44	Phase 2/Phase 3	Korea, Republic of
4	NCT01223755 (ClinicalTrials.gov)	September 2010	12/10/2010	Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal Insufficiency	EFFECTS OF SIROLIMUSON DISEASE PROGRESSION IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DIS ...	Autosomal Dominant Polycystic Kidney Disease (ADPKD)	Drug: Sirolimus;Drug: conventional therapy	Mario Negri Institute for Pharmacological Research	NULL	Terminated	18 Years	80 Years	Both	41	Phase 2/Phase 3	Italy
5	NCT01632605 (ClinicalTrials.gov)	November 2009	13/5/2012	The Vienna RAP Pilot Study	Rapamycin in Advanced Polycystic Kidney Disease Pilot Study	ADPKD	Drug: Sirolimus	Medical University of Vienna	NULL	Completed	18 Years	N/A	Both	8	N/A	Austria
6	NCT00920309 (ClinicalTrials.gov)	June 2009	12/6/2009	Rapamycinas Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarke ...	Rapamycin as Treatment for ADPKD: The Role of Biomarkers in Predicting a Response to Therapy	Autosomal Dominant Polycystic Kidney Disease	Drug: Rapamycin;Other: Standard of Care-Placebo	Yale University	NULL	Terminated	18 Years	70 Years	All	21	Phase 2/Phase 3	United States
7	EUCTR2007-005047-21-IT (EUCTR)	24/12/2007	02/07/2008	Effects of Sirolimuson disease progression in patients with Autosomal Dominant Polycystic Kidney Dis ...	Effects of Sirolimuson disease progression in patients with Autosomal Dominant Polycystic Kidney Dis ...	Autosomal Dominant Polycystic Kidney Disease (ADPKD) MedDRA version: 9.1;Level: LLT;Classification c ...	Trade Name: RAPAMUNE 100CPR RIV 1MG INN or Proposed INN: Sirolimus Trade Name: RAPAMUNE 30CPR RIV 2MG I ...	IST. DI RICERCHE FARMACOLOG. M. NEGRI	NULL	Not Recruiting			Female: yes Male: yes	40	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	Italy
8	EUCTR2007-006557-25-IT (EUCTR)	20/12/2007	18/12/2007	RAPAMYCIN FOR TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE - RAPYD-STUDY	RAPAMYCIN FOR TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE - RAPYD-STUDY	ADPKD type I MedDRA version: 9.1;Level: SOC;Classification code 10038359;Term: Renal and urinary dis ...	Trade Name: RAPAMUNE *100CPR RIV 1MG INN or Proposed INN: Sirolimus Product Name: Ramipril INN or Propos ...	AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE	NULL	Not Recruiting			Female: yes Male: yes			Italy
9	NCT00491517 (ClinicalTrials.gov)	March 2007	25/6/2007	SirolimusTreatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and ...	Sirolimus Treatment in Patients With ADPKD	Polycystic Kidney	Drug: Sirolimus;Drug: conventional therapy	Mario Negri Institute for Pharmacological Research	NULL	Completed	18 Years	80 Years	Both	22	Phase 2	Italy
10	EUCTR2006-003427-37-IT (EUCTR)	05/02/2007	27/12/2006	Sirolimustreatment in patients with autosomal dominant polycystic kidney disease renal efficacy and ...	Sirolimustreatment in patients with autosomal dominant polycystic kidney disease renal efficacy and ...	Autosomal-Dominant Polycystic Kidney Disease ADPKD MedDRA version: 9.1;Level: LLT;Classification cod ...	Trade Name: RAPAMUNE 30CPR RIV 1MG INN or Proposed INN: Sirolimus Trade Name: RAPAMUNE 30CPR RIV 2MG IN ...	IST. DI RICERCHE FARMACOLOG. M. NEGRI	NULL	Not Recruiting			Female: yes Male: yes	16	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	Italy

First Previous1 2Next Last